消化指南

订阅

MedSci主页 / 所有栏目 / 消化指南

炎症性肠病外科治疗专家共识

2020-07-30 中华医学会消化病学分会炎症性肠病学组 中华炎性肠病杂志.2020.4(3):180-199.

炎症性肠病

外科治疗是炎症性肠病多学科治疗中的重要组成部分。本共识基于循证医学依据，采用Delphi方法制定，在克罗恩病（CD）、肛周CD和溃疡性结肠炎（UC）的外科治疗方面达成初步共识意见，以期为临床工作提供指

中文标题：

炎症性肠病外科治疗专家共识

发布机构：

中华医学会消化病学分会炎症性肠病学组

发布日期：

2020-07-30

简要介绍：

外科治疗是炎症性肠病多学科治疗中的重要组成部分。本共识基于循证医学依据，采用Delphi方法制定，在克罗恩病（CD）、肛周CD和溃疡性结肠炎（UC）的外科治疗方面达成初步共识意见，以期为临床工作提供指导。

下载附件：
点击下载

(因为版权问题，不支持下载)

评论区 (20)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1012057, encodeId=f835101205e57, content=很好，为临床提供指导，排忧解惑。, beContent=null, objectType=guider, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63822007469, createdName=瑞德, createdTime=Fri Aug 27 14:31:11 CST 2021, time=2021-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=975453, encodeId=4f5a9e545389, content=终于找到了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a6c95408564, createdName=ms3000000316411397, createdTime=Mon Jun 21 13:46:15 CST 2021, time=2021-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=971860, encodeId=871f9e186013, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fcc65509559, createdName=ms9000000253984134, createdTime=Tue Jun 08 15:57:36 CST 2021, time=2021-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=912030, encodeId=5f12912030e3, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=72d72489528, createdName=124764c3m24(暂无昵称), createdTime=Wed Dec 30 00:46:53 CST 2020, time=2020-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=909438, encodeId=ed5d90943898, content=学习了，又长知识了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=837a5305959, createdName=14878565m73(暂无昵称), createdTime=Sat Dec 19 20:28:34 CST 2020, time=2020-12-19, status=1, ipAttribution=)]
    2021-08-27 瑞德

    很好，为临床提供指导，排忧解惑。

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1012057, encodeId=f835101205e57, content=很好，为临床提供指导，排忧解惑。, beContent=null, objectType=guider, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63822007469, createdName=瑞德, createdTime=Fri Aug 27 14:31:11 CST 2021, time=2021-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=975453, encodeId=4f5a9e545389, content=终于找到了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a6c95408564, createdName=ms3000000316411397, createdTime=Mon Jun 21 13:46:15 CST 2021, time=2021-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=971860, encodeId=871f9e186013, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fcc65509559, createdName=ms9000000253984134, createdTime=Tue Jun 08 15:57:36 CST 2021, time=2021-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=912030, encodeId=5f12912030e3, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=72d72489528, createdName=124764c3m24(暂无昵称), createdTime=Wed Dec 30 00:46:53 CST 2020, time=2020-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=909438, encodeId=ed5d90943898, content=学习了，又长知识了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=837a5305959, createdName=14878565m73(暂无昵称), createdTime=Sat Dec 19 20:28:34 CST 2020, time=2020-12-19, status=1, ipAttribution=)]
    2021-06-21 ms3000000316411397

    终于找到了

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1012057, encodeId=f835101205e57, content=很好，为临床提供指导，排忧解惑。, beContent=null, objectType=guider, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63822007469, createdName=瑞德, createdTime=Fri Aug 27 14:31:11 CST 2021, time=2021-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=975453, encodeId=4f5a9e545389, content=终于找到了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a6c95408564, createdName=ms3000000316411397, createdTime=Mon Jun 21 13:46:15 CST 2021, time=2021-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=971860, encodeId=871f9e186013, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fcc65509559, createdName=ms9000000253984134, createdTime=Tue Jun 08 15:57:36 CST 2021, time=2021-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=912030, encodeId=5f12912030e3, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=72d72489528, createdName=124764c3m24(暂无昵称), createdTime=Wed Dec 30 00:46:53 CST 2020, time=2020-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=909438, encodeId=ed5d90943898, content=学习了，又长知识了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=837a5305959, createdName=14878565m73(暂无昵称), createdTime=Sat Dec 19 20:28:34 CST 2020, time=2020-12-19, status=1, ipAttribution=)]
    2021-06-08 ms9000000253984134

    好

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1012057, encodeId=f835101205e57, content=很好，为临床提供指导，排忧解惑。, beContent=null, objectType=guider, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63822007469, createdName=瑞德, createdTime=Fri Aug 27 14:31:11 CST 2021, time=2021-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=975453, encodeId=4f5a9e545389, content=终于找到了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a6c95408564, createdName=ms3000000316411397, createdTime=Mon Jun 21 13:46:15 CST 2021, time=2021-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=971860, encodeId=871f9e186013, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fcc65509559, createdName=ms9000000253984134, createdTime=Tue Jun 08 15:57:36 CST 2021, time=2021-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=912030, encodeId=5f12912030e3, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=72d72489528, createdName=124764c3m24(暂无昵称), createdTime=Wed Dec 30 00:46:53 CST 2020, time=2020-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=909438, encodeId=ed5d90943898, content=学习了，又长知识了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=837a5305959, createdName=14878565m73(暂无昵称), createdTime=Sat Dec 19 20:28:34 CST 2020, time=2020-12-19, status=1, ipAttribution=)]
    2020-12-30 124764c3m24(暂无昵称)

    学习

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1012057, encodeId=f835101205e57, content=很好，为临床提供指导，排忧解惑。, beContent=null, objectType=guider, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63822007469, createdName=瑞德, createdTime=Fri Aug 27 14:31:11 CST 2021, time=2021-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=975453, encodeId=4f5a9e545389, content=终于找到了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a6c95408564, createdName=ms3000000316411397, createdTime=Mon Jun 21 13:46:15 CST 2021, time=2021-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=971860, encodeId=871f9e186013, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fcc65509559, createdName=ms9000000253984134, createdTime=Tue Jun 08 15:57:36 CST 2021, time=2021-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=912030, encodeId=5f12912030e3, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=72d72489528, createdName=124764c3m24(暂无昵称), createdTime=Wed Dec 30 00:46:53 CST 2020, time=2020-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=909438, encodeId=ed5d90943898, content=学习了，又长知识了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=837a5305959, createdName=14878565m73(暂无昵称), createdTime=Sat Dec 19 20:28:34 CST 2020, time=2020-12-19, status=1, ipAttribution=)]
    2020-12-19 14878565m73(暂无昵称)

    学习了，又长知识了

    0

以上为热门评论，梅斯医学App还有更多内容

相关指南

炎症性肠病病理诊断专家建议

中华医学会消化病学分会炎症性肠病学组 · 2020-03-30

2020 SICCR炎症性肠病立场声明：克罗恩病

意大利结直肠外科学会(SICCR,Italian society of colorectal surgery) · 2020-03-14

关于炎症性肠病患者有效预防和治疗SARS-CoV-2 感染的共识

中国医药教育协会 · 2020-02-20

2020 SICCR炎症性肠病立场声明：溃疡性结肠炎

意大利结直肠外科学会(SICCR,Italian society of colorectal surgery) · 2020-03-02

2020 KASID临床实践指南：炎症性肠病患者病毒性肝炎的预防和管理

国外消化科相关专家小组（统称） · 2020-01-28

2020 CAG/CCC立场声明：生物仿制药治疗炎症性肠病

加拿大胃肠病学协会(CAG,The Canadian Association of Gastroenterology) · 2020-02-03

拓展阅读

2014年加拿大炎症性肠病（IBD）与静脉血栓防治共识意见：加拿大胃肠病学会

加拿大胃肠病学协会(CAG,The Canadian Association of Gastroenterology) · 2014-03-01

2014 ESPGHAN儿童和青少年炎症性肠病诊断的波尔图标准（修订版）

欧洲儿科胃肠病学、肝病学和营养协会(ESPGHAN,European Society for Paediatric Gastroenterology, Hepatology, and Nutrition) · 2014-06-10

2014 CAG立场声明：应用巯嘌呤类药物治疗炎症性肠病

加拿大胃肠病学协会(CAG,The Canadian Association of Gastroenterology) · 2014-07-04

2015 ASGE指南：内镜检查在炎症性肠病中的作用

美国胃肠内镜学会(ASGE,American Society for Gastrointestinal Endoscopy) · 2015-03-20

2016 建立我国炎症性肠病诊治中心质量控制指标的共识

中华医学会消化病学分会炎症性肠病学组 · 2016-07-30

2017 IG-IBD临床实践指南：应用糖皮质激素和免疫抑制药物治疗炎症性肠病

意大利炎症性肠病研究组(IG-IBD,Italian Group for the Study of Inflammatory Bowel Disease) · 2017-01-25